Report of Foreign Issuer (6-k)
January 31 2020 - 4:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2020
Commission File Number: 001-38547
Autolus Therapeutics plc
(Translation of registrants name into English)
Forest House
58 Wood Lane
White City
London W12
7RZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F
☐ Form 40-F
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On January 30, 2020, Autolus Therapeutics plc (the Company) issued a press release titled
Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers. The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.
Information in the attached Exhibit 99.1 is being furnished and this exhibit shall not be deemed filed for the purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of
1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
EXHIBIT LIST
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Press Release dated January 30, 2019, Autolus Therapeutics Presents Encouraging Additional Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Autolus Therapeutics plc
|
|
|
|
|
Date: January 31, 2020
|
|
|
|
By:
|
|
/s/ Christian Itin
|
|
|
|
|
|
|
Name: Christian Itin, Ph.D.
|
|
|
|
|
|
|
Title: Chief Executive Officer
|